• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • News
  • Lifestyle
  • Wellness
  • Cuisine
  • Product Reviews
  • Subscribe
Cannabis News and Culture Magazine

Cannabis News and Culture Magazine

Cannabis News and Culture Magazine

Emerald Media News Subscription
  • Print Magazines
  • 100+ Minority-Owned Companies to Support
  • No Pipe, No Problem
  • Blunt vs. Joint
  • The Cost of Cannabis in Each State
  • Calculating Your Edibles Dosage
  • Flintts Mouthwatering Mints

GB Sciences and University of Athens, Greece, Embark on Next-Level Drug Discovery Examining Cannabis-Based, Disease-Modifying Compounds

October 4, 2018 by Emerald Media Group Leave a Comment

This information was provided by prnewswire

Send your Press Release here.

GB Sciences explores the therapeutic potential of the chemical diversity within different varieties of the cannabis plant to make better medicine for patients worldwide.

LAS VEGAS, Oct. 3, 2018 /PRNewswire/ — GB Sciences, Inc. (OTCQB: GBLX) initiates a new project with the Department of Pharmacognosy and Natural Products Chemistry at the National Kapodistrian University of Athens, Greece.  Titled: The Cannabis Metabolomics (“Canna-bolomics”) Project, the program will analyze each of GB Sciences’ cultivars to determine whether additional molecules in these cultivars, and hundreds of other natural cannabis and hemp cultivars, show significant promise to treat diseases.

 

“GB Sciences is widening the lens with which we observe and characterize plant-based, cannabis-derived chemical mixtures for human therapies starting from GB Sciences’ stock genotypes. Standard potency assays in Nevada only measure about ten cannabinoids and twenty-one terpenoids, whereas, metabolomic analyses allow us to measure all of the molecules in these mixtures to identify new compounds that potentially provide additional medical benefits for new patent-pending therapeutic mixtures,” explains Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences.  “In addition, we will look for disease-modifying compounds in other Cannabis genotypes using both functional assays and full metabolomic studies performed in parallel between GB Sciences and the University of Athens, respectively. Together, we can make better medicines that capitalize on the diversity of the biology of the plant.”

GB Sciences’ current research efforts has yielded multiple patent applications containing novel cannabinoid-containing complex mixtures (CCCM™) composed of cannabinoids and terpenoids that work synergistically. While the complex mixtures in GB Sciences current patent applications show clinical promise, GB Sciences had been limited in defining the formulations by their current method of measuring the secondary metabolites using third-party testing labs in Nevada.

Professor Leandros Skaltsounis, Director of Pharmacognosy and Natural Products Chemistry of the University of Athens says, “The University of Athens welcomes this very important collaboration. In fact, this is our first international collaboration in this extremely important field. This project will increase our knowledge on chemical composition and enable us to better select the appropriate cannabis compounds to develop the next generation of therapeutic medicines.”

John Poss, CEO and Chairman of GB Sciences says, “GB Sciences is excited about our new Canna-bolomics Project with the University of Athens. The potential for metabolomics methods to expand our formulations and improve the efficacy of our cannabis-based human therapies could bring our cannabis-based drug discovery efforts to the next level.”

“This announcement is an important moment for medical cannabis research and Greece’s emerging cannabis industry,” said Annie Camarioti, co-founder of the Athens-based cannabis consultancy Medicanna, “The collaboration brings together GB Sciences’ unparalleled cannabinoid expertise with the University of Athens’ extraordinary faculty. It’s a vital new chapter for cannabis research and for our country.”  

Filed Under: Press Release Tagged With: Press

Reader Interactions

Leave a Reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube

Advertise Here

Categories

Sustainability

seaweed naturals

SeaWeed Naturals Combines the Power of Seaweed with Cannabis to Further Ocean Restoration

April 3, 2022 By Maggie Horton

fungi climate change

Research Finds Fungi Help Ease Climate Change and Benefit the Environment

March 30, 2022 By Julia Meyer

climate crisis and the pandemic

“We Can Act:” What Bending the COVID-19 Curve Teaches Us About the Climate Crisis

April 21, 2020 By Melissa Hutsell

Footer

  • Subscribe
  • About
  • Contact
  • Privacy
  • Press

Recent

  • Priscilla Vilchis and Lil Kim Launch Aphrodisiak: A Cannabis Brand Focused on Sensuality, Social Justice, and Inclusivity
  • First Latina CEO of a Cannabis Company Partners with Music Industry Trailblazer Lil Kim to Launch Aphrodisiak Brand
  • Aphrodisiak: The New Female-Led Cannabis Brand Empowering Women and Promoting Inclusivity
  • Las Vegas Welcomes Aphrodisiak
  • HighOnLove – Taking Pleasure to New Heights

Search

Copyright © 2023 · The Emerald™ · News & Lifestyle Magazine

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

Cannabis News and Culture Magazine
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.